Mark J. Ratain to Drug Design
This is a "connection" page, showing publications Mark J. Ratain has written about Drug Design.
Connection Strength
0.349
-
Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007 Oct; 82(4):381-8.
Score: 0.074
-
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol. 2006 Jul; 62(1):35-46.
Score: 0.069
-
Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene. 2003 Sep 29; 22(42):6621-8.
Score: 0.057
-
Development of target-based antineoplastic agents. Invest New Drugs. 2000 Feb; 18(1):7-16.
Score: 0.044
-
Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov; 8(6):525-34.
Score: 0.035
-
Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
Score: 0.024
-
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
Score: 0.023
-
Dose-escalation models for combination phase I trials in oncology. Eur J Cancer. 2010 Nov; 46(16):2870-8.
Score: 0.023